In a remarkable case, Penn Medicine researchers used an AI-driven platform to identify adalimumab—a drug already approved for other conditions—as a life-saving treatment for a patient with idiopathic multicentric Castleman’s disease (iMCD).

MoodSensing, an innovative app developed in Taiwan, uses digital phenotyping and engaging features to track bipolar disorder symptoms. With impressive predictive accuracy, it promises to revolutionize mental health care while prioritizing user experience and privacy.